相关实验视频

Updated: May 22, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

在CREscendoing承诺的HDAC的目标是限制动脉样硬化症

Máté G Kiss¹, Christoph J Binder¹

¹Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

|March 12, 2025

概括

一个cis调节元件 (CRE) 的遗传变异会影响动脉样硬化炎症. 这项研究表明,NLRP3的基因组脱乙酶9 (HDAC9) 脱乙化是将CRE变异与动脉样硬化炎症过程联系起来的关键机制.

科学领域:

心血管生物学心血管生物学
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

动脉样硬化的炎症反应尚未完全理解.
影响动脉样硬化风险的遗传因素需要进一步调查.

研究的目的:

为了研究一个特定的cis-regulatory元素 (CRE) 在控制HDAC9表达中的作用.
阐明这种CRE中遗传变异影响人类动脉样硬化相关炎症的机制.

主要方法:

对影响HDAC9表达的保守的cis调节元件 (CRE) 的分析.
研究HDAC9在NLRP3脱乙烯化中的作用.
遗传变异与动脉样硬化的炎症过程的相关性.

主要成果:

保守的CRE显著影响HDAC9的表达.
HDAC9调解了NLRP3.3的脱乙化过程.
这种HDAC9-介导的脱乙基化是一种潜在的机制,可以将CRE变异与动脉样硬化炎症联系起来.

结论:

保存的CRE中的遗传变异通过调节HDAC9表达来影响动脉样硬化.
鉴于HDAC9依赖的NLRP3脱乙烯化,它被认为是动脉样硬化相关炎症的关键机制.

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

相关概念视频

Inflammation

Inflammation

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...